Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Inlyta (axitinib) / Pfizer

NCT01473043: Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment

No Longer Available

N/A

Canada, RoW

Axitinib, AG-013736

Pfizer

Renal Cell Carcinoma

03/14

NCT02354612: Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

No Longer Available

N/A

TRC105, Chimeric Antibody (TRC105) to CD105, Bevacizumab, Avastin, Axitinib, Inlyta, Pazopanib, Votrient, Capecitabine, Xeloda

Tracon Pharmaceuticals Inc.

Solid Tumors

ChiCTR2000030405: Study of Efficacy and Safety of Preoperative Axitinib Combined with Toripalimab in Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus: a Clinical Multicentric Prospective Study

Recruiting

N/A

China

axitinib combined with toripalimab

Chinese PLA General Hospital ; Chinese PLA General Hospital, Project supported by the National Natural Science Foundation of China (Grant No. 81972389)

Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus

ChiCTR2000029057: A phase II clinical study of Axitinib combined with Tripletiumab (JS001) and SBRT for locally advanced metastatic renal cell carcinoma

Not yet recruiting

N/A

Axitinib, Tripletiumab and SBRT

Sun Yat-sen University Cancer Center; Sun Yat-Sen University Cancer Center, self-raised funding

metastatic renal cell carcinoma

NCT05941637: An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)

Available

N/A

Axitinib 5 MG, INLYTA, AG-013736

Lynkcell Europe

Clear Cell Kidney Cancer, Kidney Cancer, Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations

NCT05650164: Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)

Completed

N/A

171

Japan

avelumab, axitinib

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Renal Cell Carcinoma

10/23

A4061008, NCT00828919 / 2005-000051-15: Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

Completed

N/A

Europe, Japan, US, RoW

axitinib, AG-013736, crizotinib, PF-02341066

Pfizer

Solid Tumors

08/23

NCT05394493: An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

Completed

N/A

130

Europe

avelumab, axitinib

Pfizer

Advanced Renal Cell Carcinoma

08/23

NCT05816642: Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Recruiting

N/A

500

RoW

sunitinib or pazopanib, PD-1 inhibitor combined with axitinib

RenJi Hospital, Ruijin Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, West China Hospital, Xiangya Hospital of Central South University, Fudan University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Second Affiliated Hospital of Nantong University, Peking University First Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Sir Run Run Shaw Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The General Hospital of Eastern Theater Command, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of University of Science and Technology of China, The Second Hospital of Anhui Medical University, Tongji Hospital, The First Affiliated Hospital of Zhengzhou University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, The First Affiliated Hospital of Shanxi Medical University, Shanxi Provincial Cancer Hospital, Changzhi Medical College, First Affiliated Hospital Xi'an Jiaotong University, Second Affiliated Hospital of Xi'an Jiaotong University, Xijing Hospital of Air Force Military Medical University, Tang-Du Hospital, Quanzhou First Hospital Affiliated to Fujian Medical University, Third Affiliated Hospital, Sun Yat-Sen University

Metastatic Renal Cell Carcinoma

12/23

12/24

ALARICE, NCT03826589: Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy

Active, not recruiting

N/A

RoW

Avelumab, Bavencio, Axitinib, Inlyta

The University of Hong Kong

Cervical Cancer

03/24

07/24

AVION, NCT04941768: An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC

Active, not recruiting

N/A

108

Europe, RoW

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare Germany GmbH, an affiliate of Merck KGaA, Darmstadt, Germany

Carcinoma, Renal Cell

08/24

05/25

NCT05287464: International Multicentric Study ARON-1

Recruiting

N/A

1220

Europe

pembrolizumab plus axitinib, nivolumab plus cabozantinib, pembrolizumab plus lenvatinib, nivolumab plus ipilimumab, avelumab plus axitinib, atezolizumab plus bevacizumab

Hospital of Macerata

Metastatic Renal Cell Carcinoma (mRCC)

06/24

12/24



	Diseases Companies Products Productz Mechanisms of Action Sites